Dihexa
Animal / preclinicalAlso known as: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, PNB-0408
Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.
Overview
A small angiotensin IV–derived peptide developed in preclinical Alzheimer's research for its potent synapse-forming effects. There is no human trial evidence, and its mechanism raises unanswered safety questions.
Mechanism
Proposed to enhance hepatocyte growth factor (HGF)/c-Met signalling, promoting synaptogenesis in animal models.
Evidence
Very thin: striking rodent synaptogenesis data but no human studies; potent growth-factor signalling warrants caution rather than enthusiasm.
Community-reported information
Community reports vary. Anecdotal, unvalidated and poorly characterised; general information only.
General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.
Half-life
Not well characterised in humans (oral/transdermal use reported).
Storage
Store cool and dark.
Commonly reported side effects
- Not well characterised in humans
Legal status by region
- USNot FDA-approved; not a lawful supplement ingredient.
Legal status changes over time; verify locally before relying on this.